ClinicalTrials.gg
RecruitingNCT05294978Updated Jul 31, 2025

EyeConic: Qualification for Cone-Optogenetics

An observational study in Retinal Dystrophies, sponsored by Institute of Molecular and Clinical Ophthalmology Basel. Recruiting at 9 sites in 7 countries. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Institute of Molecular and Clinical Ophthalmology Basel · Observational

How we know

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Retrospective
Enrollment
1,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Retinal Dystrophies with a site in United States — 8 open to participants now, 16 under way, none of them phase 3. Retinal Dystrophies · United States.

Planned enrollment
2nd of 11
1,000 · median 35
Started
2021
with 1 other
Observational
11 of 27
4 open now
Primary completion
2026-12
later than 4 of 14 live
Registered
11th of 27
by date
Lead sponsor
1 of 27
Institute of Molecular and Clinical Ophthalmology Basel

Among the 27 studies in Retinal Dystrophies with a site in United States, this one is the 2nd largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2021, is one of 11 observational ones, reaches primary completion later than 4 of the 14 other live ones, and was the 11th registered.

Retinal Dystrophies

60 studies on the registry are indexed under Retinal Dystrophies; 20 are open to participants now.

Browse Retinal Dystrophies studies →

Open to participants now

8 of the 27 studies in Retinal Dystrophies with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Retinal Dystrophies studies recruiting now, 11 (65%) set no upper age limit and 3 (18%) stop at 75 or younger; 6 take children under 18; 5 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Retinal Dystrophies with a site in United States, or all of them as a file.
02

Study summary

This study aims to prepare for the first-in-human clinical trial of cone optogenetics vision restoration. As a first step, this worldwide multicenter ocular imaging study (EyeConic Study) is performed to identify eligible patients.

Read the detailed description

In a subset of patients with inherited retinal dystrophies (IRDs), cones lose their light-sensitive outer segments but remain alive in a dormant stage. This creates an opportunity to resensitize them through targeted optogenetic tools. However, the true proportion of low vision patients harboring dormant, non-functional cones, is currently unknown. The worldwide multicenter retrospective study (EyeConic) aims to estimate the proportion of low vision patients with remaining cone cell bodies for the first time.

03

Conditions studied

  • Retinal Dystrophies

Keywords

  • Cone-Optogenetics
  • Rod-cone Dystrophy
  • Cone-rod Dystrophy
  • Generalized retinal dystrophies
  • Inherited retinal disease
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

  • Patients with diagnosis of generalized retinal dystrophy
  • Normal controls

Eligibility criteria

Inclusion Criteria (patients):

  • Diagnosis of generalized IRD
  • Low vision as defined as visual acuity worse or equal to 0.05 (or 20/400) in the study eye
  • Availability of macular optical coherence tomography (OCT)

Inclusion Criteria (controls):

  • Normal ophthalmic findings
  • Availability of macular optical coherence tomography (OCT)

Exclusion Criteria (all):

  • Other eye diseases with a significant effect on vision or retinal structure
  • Extraocular disease affecting retinal structure such as neurodegenerative diseases
05

Study design

Observational model
Case-control
Time perspective
Retrospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients

    -Availability of macular optical coherence tomography (OCT)

    Diagnostic Test: Optical coherence tomography (OCT)

  • Controls

    -Availability of macular optical coherence tomography (OCT)

    Diagnostic Test: Optical coherence tomography (OCT)

Interventions

  • Diagnostic testOptical coherence tomography (OCT)

    Data of macular optical coherence tomography (OCT)

06

What researchers measure

Primary outcomes

  1. OCT - Central retinal volume

    Number of participants with preserved central retinal volume

    Time frame: Baseline (about 10 minutes)

07

Study locations

9 of 9 sites recruiting
  • University of California San Francisco, Department of Ophthalmology
    San Francisco, California 94158, United States
    Recruiting
    • Jacque Duncan, MD · Principal investigator
  • Bascom Palmer Eye Institute
    Miami, Florida 33136, United States
    Recruiting
    • Byron L Lam, MD · Principal investigator
    • Potyra Rosa, MD · Sub investigator
  • University of Pittsburgh, Department of Ophthalmology
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
    • Jose A Sahel, MD · Principal investigator
    • Boris Rosin, MD · Sub investigator
    • Michelle Alabek, MD · Sub investigator
  • Beijing Institute of Ophthalmology
    Beijing, China
    Recruiting
    • Jin Zi-Bing, MD · Principal investigator
    • Shen Ren-Zuan, MD · Sub investigator
  • Universitätsklinikum Tübingen Augenklinik
    Tübingen, Germany
    Recruiting
    • Katarina Stingl, MD · Principal investigator
    • Melanie Kempf, MSc · Sub investigator
  • Semmelweis University, Department of Ophthalmology
    Budapest, Hungary
    Recruiting
    • Nagy Zoltan, MD · Principal investigator
    • Viktoria Szabo, MD · Sub investigator
  • Oculista Ospedale Parma
    Parma, Italy
    Recruiting
    • Stefano Gandolfi, MD · Contact
    • Giacomo Calzetti, MD · Principal investigator
  • University Hospital Basel, Eye Clinic
    Basel, 4031, Switzerland
    Recruiting
    • Nicolas Feltgen, MD · Contactnicolas.feltgen@usb.ch · +41612659292
    • Nicolas Feltgen, MD · Principal investigator
    • Bence György, MD · Sub investigator
    • Lucas Janeschitz-Kriegl, MD · Sub investigator
  • Moorfields Eye Hospital
    London, United Kingdom
    Recruiting
    • Michel Michalides, MD · Principal investigator
    • Michalis Georgiu, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2021 (actual). Primary completion is estimated for Dec 2026, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2022
First posted
Mar 24, 2022
StartActual
Jul 1, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05294978
Lead sponsor
Institute of Molecular and Clinical Ophthalmology Basel
Responsible party
Sponsor
First posted
Mar 24, 2022
Start date
Jul 1, 2021
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 31, 2025

Study contacts

Lucas Janeschitz-Kriegl, MD
Contact
lucas.janeschitz@iob.ch
+41787494373
Tiana Koottungal
Contact
tiana.koottungal@iob.ch
+41788486737
Nicolas Feltgen, MD
principal investigator · University Hospital Basel/Institute of Molecular and Clinical Ophthalmology Basel, Switzerland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion